What's in Amphastar Pharmaceuticals, Inc.'s pipeline?

Amphastar Pharmaceuticals, Inc. has 14 drugs in our index: 3 marketed, 0 filed, 4 in Phase 3, 6 in Phase 2, 1 in Phase 1.

Which companies overlap with Amphastar Pharmaceuticals, Inc.'s portfolio?

Top competitors by shared drug class: Teva Branded Pharmaceutical Products R&D, Inc., AstraZeneca, GlaxoSmithKline, Sumitomo Pharma America, Inc., Merck Sharp & Dohme LLC.

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/amphastar-pharmaceuticals-inc.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-05-16 · How we verify

Amphastar Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief

Amphastar Pharmaceuticals, Inc. pipeline: 3 marketed, 0 filed, 4 Phase 3, 6 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

3 marketed 0 filed 4 Phase 3 6 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area
Primatene Mist	Primatene Mist	marketed	Beta-2 adrenergic agonist (short-acting)	Beta-2 adrenergic receptor	Respiratory
Placebo DPI	Placebo DPI	marketed
Epinephrine inhalation	Epinephrine inhalation	marketed	Adrenergic agonist bronchodilator	Alpha-1, beta-1, and beta-2 adrenergic receptors	Pulmonology / Respiratory
albuterol inhalation powder	albuterol inhalation powder	phase 3	Beta-2 adrenergic agonist (short-acting bronchodilator)	Beta-2 adrenergic receptor	Respiratory
epinephrine inhalation aerosol	epinephrine inhalation aerosol	phase 3	Adrenergic agonist	beta-2 adrenergic receptor	Respiratory
albuterol inhalation aerosol	albuterol inhalation aerosol	phase 3	Beta-2 adrenergic receptor agonist	Beta-2 adrenergic receptor	Respiratory
Epinephrine HFA-MDI (E004)	Epinephrine HFA-MDI (E004)	phase 3	Sympathomimetic amine / Adrenergic agonist	Alpha-1 adrenergic receptor, Beta-2 adrenergic receptor	Pulmonary / Emergency Medicine

Therapeutic area mix

Respiratory · 5
Diabetes · 1
Pulmonary / Emergency Medicine · 1
Pulmonology / Respiratory · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Teva Branded Pharmaceutical Products R&D, Inc. · 4 shared drug classes
AstraZeneca · 3 shared drug classes
GlaxoSmithKline · 3 shared drug classes
Sumitomo Pharma America, Inc. · 2 shared drug classes
Merck Sharp & Dohme LLC · 2 shared drug classes
Sanofi · 2 shared drug classes
Ache Laboratorios Farmaceuticos S.A. · 1 shared drug class
AceLink Therapeutics, Inc. · 1 shared drug class

Subscribe to ongoing alerts

Every new pipeline event for Amphastar Pharmaceuticals, Inc.:

Cite this brief

Drug Landscape (2026). Amphastar Pharmaceuticals, Inc. — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/amphastar-pharmaceuticals-inc. Accessed 2026-05-16.